ClinicalTrials.gg
CompletedNCT06550817Updated Aug 13, 2024

Growth Mindset Intervention for Older Adults With Chronic Disease

An interventional study of Growth mindset intervention and E-health Program in Chronic Disease, sponsored by Huzhou University. Completed at 2 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Huzhou University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Sep 2021, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This study was conducted to develop and investigate the effectiveness of a growth mindset intervention based on growth mindset theory.

Read the detailed description

The study employed a quasi-randomized controlled trial design conducted over 12 weeks. Before conducting the study, the researchers numbered the wards of internal medicine departments (excluding intensive care units) according to the order of bed number. The wards were then randomly divided into intervention wards and control wards using a random number generator. Patients were recruited to the control group (e-health only) in the control ward and the intervention group (growth mindset intervention+ e-health) in the intervention unit. Participants in the control group could undergo the training after the study concluded.

02

Conditions studied

  • Chronic Disease

Browse trials for

03

In context

Chronic Disease

782 studies on the registry are indexed under Chronic Disease; 144 are open to participants now.

This study's enrollment of 77 is below the median of 140 across 582 interventional studies indexed under Chronic Disease.

Browse Chronic Disease studies →

Lead sponsor

Huzhou University is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged≥60 years
  • diagnosed≥1 chronic disease
  • owned at least one smartphone
  • could communicate clearly in writing or orally
  • were willing to participate in this study

Exclusion criteria

Exclusion Criteria:

  • could not use WeChat or phone to communicate
  • diagnosed as mental illness or cognitive impairment
  • suffered from acute severe disease or lost self-care ability
  • undergoing other similar training
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    growth mindset + e-health

    Participants received an e-health program intervention plus a growth mindset intervention over 12 weeks, with weekly sessions for the first 6 weeks and biweekly follow-up phone calls for the next six weeks.

    Other: Growth mindset intervention

  • Active comparator
    e-health only

    Participants received an e-health program intervention over 12 weeks, with weekly sessions for the first 6 weeks and biweekly follow-up phone calls for the next six weeks.

    Other: E-health Program

Interventions

  • OtherGrowth mindset intervention

    Online intervention is implemented and it lasts about 20 minutes each time, while face-to-face intervention lasts about 30 minutes each time, and they are carried out for a total of six weeks, face-to-face or telephone intervention is implemented once every two weeks for about 15 minutes each time

  • OtherE-health Program

    face-to-face e-health teaching in the first 6 weeks, and telephone follow-up were conducted once a week, for about 10 minutes each time in the last 6 weeks

06

What researchers measure

Primary outcomes

  1. Implicit Theories of Intelligence Scale-6

    The Implicit Theories of Intelligence Scale-6 (ITIS-6) is a validated, self-reported instrument assessing participants' level of growth mindset. A mean score of greater than or equal to 4 on all items indicates that the individual has a growth mindset, and vice versa for a fixed mindset.

    Time frame: Baseline,Week 6, and Week 12

  2. Questionnaire of Knowledge, Willingness, Confidence, and Practice of Smart Medicine (KWCP-SM)

    The Questionnaire of Knowledge, Willingness, Confidence, and Practice of Smart Medicine (KWCP-SM) is a validated, self-reported instrument assessing participants' level of knowledge, willingness, confidence, and practice of smart medicine. The questionnaire adopted the Likert-5 scoring method. The higher score indicated a higher level of knowledge, willingness, confidence, and practice of smart medicine.

    Time frame: Baseline,Week 6, and Week 12

07

Study locations

2 sites
  • School of Medicine and Nursing, Huzhou University
    Huzhou, Zhejiang 313000, China
  • School of Nursing Huzhou University
    Huzhou, Zhejiang 313000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2022, 13 months.

Of 319 non-industry interventional studies with no phase under Chronic Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's 13 months is below that.

Counting every sponsor, half of 329 studies reached it within 21 months; a quarter within 11 and three quarters within 33.

Chronic Disease covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 13, 2024
StartActual
Sep 1, 2021
Primary completionActual
Oct 31, 2022
CompletionActual
Oct 31, 2022
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06550817
Lead sponsor
Huzhou University
Responsible party
Yaling Zeng (Principal Investigator, Huzhou University) — Principal investigator
First posted
Aug 13, 2024
Start date
Sep 1, 2021
Primary completion
Oct 31, 2022
Completion
Oct 31, 2022
Last update
Aug 13, 2024

Study contacts

Meijuan Cao
study chair · Huzhou University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion